Skip to main content
PCVX
NASDAQ Life Sciences

Vaxcyte's Q3 Loss Beats Estimates; VAX-31 BLA Filing Slated for 1H 2028

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$65.68
Mkt Cap
$10.337B
52W Low
$39.87
52W High
$90.75
52W Position info
65% above low
Off High info
28% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

PCVX sits 65% above its 52-week low of $39.87.

Summary

Vaxcyte posted a Q3 net loss of $297.06 million, narrower than the $310.72 million consensus from eight analysts, with operating expenses up 27% year over year to $308.27 million on VAX-31 Phase 3 trial, manufacturing and personnel costs. The company now guides to OPUS-2 and OPUS-3 Phase 3 results in the first half of 2027, VAX-31 infant Phase 2 topline data by the end of that same half, and a BLA submission for the adult indication in the first half of 2028. This follows the October 5 OPUS-1 win, where VAX-31 met all primary immunogenicity and safety endpoints, and the roughly $1.1 billion raised in the concurrent equity and convertible offerings that closed October 9. The cash position is the story: about $3.4 billion pro forma gives Vaxcyte room to fund the remaining Phase 3 readouts and build out manufacturing without another raise. The 2028 filing date is the key number — it sets the commercial timeline for the adult franchise and frames how long the market waits before revenue.

At the time of this announcement, PCVX was trading at $65.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.3B. The 52-week trading range was $39.87 to $90.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

PCVX - Latest Insights

PCVX
Nov 04, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $65.68
Real-time Price: $55.30 info
Change: -$10.38 (-16%) info
Market Cap: $8.82B info
PCVX
Oct 09, 2026, 4:42 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $71.12
Real-time Price: $55.30 info
Change: -$15.82 (-22%) info
Market Cap: $8.82B info
PCVX
Oct 08, 2026, 4:30 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $64.94
Real-time Price: $55.30 info
Change: -$9.64 (-15%) info
Market Cap: $8.82B info
PCVX
Oct 07, 2026, 6:05 AM EDT
Filing Type: FWP
Importance Score:
8
Price at Filing: $66.40
Real-time Price: $55.30 info
Change: -$11.10 (-17%) info
Market Cap: $8.82B info
PCVX
Oct 06, 2026, 10:50 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $66.70
Real-time Price: $55.30 info
Change: -$11.40 (-17%) info
Market Cap: $8.82B info